Royal Bank of Canada
TEVA icon

Royal Bank of Canada’s Teva Pharmaceuticals TEVA Stock Holding History

Royal Bank of Canada’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-163,500
Closed -$1.32M – 7713
2022
Q3 		$1.32M Buy
+163,500
New +$1.45M ﹤0.01% 3195
2022
Q1 		– Sell
-326,300
Closed -$2.61M – 8007
2021
Q4 		$2.61M Buy
+326,300
New +$2.95M ﹤0.01% 2921
2021
Q1 		– Sell
-446,700
Closed -$4.31M – 7692
2020
Q4 		$4.31M Buy
+446,700
New +$4.28M ﹤0.01% 2289
2020
Q1 		– Sell
-374,800
Closed -$3.67M – 7016
2019
Q4 		$3.67M Sell
374,800
-698,000
-65% -$6.23M ﹤0.01% 2390
2019
Q3 		$7.38M Buy
1,072,800
+166,200
+18% +$1.27M ﹤0.01% 1790
2019
Q2 		$8.37M Buy
906,600
+415,400
+85% +$5.01M ﹤0.01% 1691
2019
Q1 		$7.7M Sell
491,200
-326,400
-40% -$5.76M ﹤0.01% 1695
2018
Q4 		$12.6M Buy
817,600
+250,100
+44% +$5.13M 0.01% 1301
2018
Q3 		$12.2M Hold
567,500
– – 0.01% 1469
2018
Q2 		$13.8M Hold
567,500
– – 0.01% 1314
2018
Q1 		$9.7M Sell
567,500
-1,460,000
-72% -$28.5M ﹤0.01% 1561
2017
Q4 		$38.4M Buy
2,027,500
+922,500
+83% +$13.9M 0.02% 754
2017
Q3 		$19.4M Buy
1,105,000
+655,000
+146% +$14.7M 0.01% 1101
2017
Q2 		$14.9M Sell
450,000
-326,700
-42% -$10.1M 0.01% 1249
2017
Q1 		$24.9M Sell
776,700
-438,500
-36% -$15M 0.01% 889
2016
Q4 		$44.1M Buy
1,215,200
+586,600
+93% +$23.4M 0.02% 571
2016
Q3 		$28.9M Buy
628,600
+325,000
+107% +$17M 0.02% 775
2016
Q2 		$15.3M Sell
303,600
-429,900
-59% -$22.9M 0.01% 1134
2016
Q1 		$39.3M Buy
733,500
+154,400
+27% +$9.06M 0.02% 565
2015
Q4 		$38M Buy
579,100
+114,900
+25% +$7.1M 0.03% 570
2015
Q3 		$26.2M Buy
464,200
+9,200
+2% +$597K 0.02% 626
2015
Q2 		$26.9M Buy
455,000
+305,000
+203% +$18.8M 0.02% 652
2015
Q1 		$9.35M Hold
150,000
– – 0.01% 1248
2014
Q4 		$8.63M Hold
150,000
– – 0.01% 1301
2014
Q3 		$8.06M Buy
150,000
+112,400
+299% +$5.95M 0.01% 1336
2014
Q2 		$1.97M Buy
+37,600
New +$1.92M ﹤0.01% 2308

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royal Bank of Canada's TEVA Position: Q1 2026 in Review

Royal Bank of Canada increased its Teva Pharmaceuticals (TEVA) stake by 11% in Q1 2026, buying an estimated $3.12M and bringing the position to 963,824 shares worth $29M. The position accounts for 0.01% of the portfolio, ranked #1207.

Royal Bank of Canada first reported a position in TEVA in Q2 2013 and has held it in 52 quarters since. The position peaked at $130M in Q2 2013. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Royal Bank of Canada held 963,824 shares of Teva Pharmaceuticals worth $29M as of Q1 2026.
  • Royal Bank of Canada bought 96,938 Teva Pharmaceuticals shares in Q1 2026, an estimated $3.12M.
  • Teva Pharmaceuticals made up 0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #1207 holding.
  • Royal Bank of Canada first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Royal Bank of Canada's Teva Pharmaceuticals position peaked at $130M in Q2 2013.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.